替罗非班治疗急性心肌梗死患者发生血小板减少症的临床分析(2)
http://www.100md.com
2011年2月5日
 |
| 第1页 |
参见附件(3869KB，3页)。
[2] Crouch MA,Napp i JM,Cheang KI.GlycoproteinⅡb/Ⅲa receptor inhibitors in percutaneous coronary intervention and acute coronary syndrome.Ann Pharmacother,2003,37(6):860-875.
[3] Dasgup ta H,B lankenship JC,Wood GC,et al.Thrombocytopenia complicating treatment with intravenous glycoprotein Ⅱb/Ⅲa receptor inhibitors:a pooled analysis.Am Heart J,2000,140:206-211.
[4] Huxtable LM,TafreshiMJ,Rakkar AN.Frequency and management of thrombocytopenia with the glycop rotein Ⅱb / Ⅲa receptor antagonists.Am J Cardiol,2006,97:4262429.
[5] Razakjr OA,Tan HC,Yip WL,et al.Predictors of bleeding complications and thrombocytopenia with the use of abciximab during percutaneous coronary intervention.J Interv Cardiol,2005,18:33-37.
[6] The RESTORE Investigators.Effects of platelet glycoprotein Ⅱb/Ⅲa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty.Circulation,1997,96:1445-1453.
[7] Platelet receptor inhibition in ischemic syndrome management in patients limited by unstable sign and symptoms(PRISM-PLUS)study investigators.Inhibition of the platelet glycoproteinⅡb/Ⅲa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction.N Engl Med,1998,338:1488-1497.
[8] Berkowitz SD,Sane DC,Sigmon KN,et al.Occurrence and clinical significance of thrombocytopenia in a population undergoing high-risk percutaneous coronary revascularization.Evaluation of c7E3 for the Prevention of Ischemic Complications(EPIC)Study Group.J Am Coll Cardiol,1998,32:311-319.
[9] Bougie DW,W ilker PR,W uitschick ED,et al.Acute thrombocytopenia after treatment with tirofiban or eptifibatide is associatied with antibodies specific for ligand-occupied GP Ⅱb / Ⅲa.Blood,2002,100:2071-2076.
您现在查看是摘要介绍页，详见PDF附件(3869KB，3页)。